Observation Of Bifidobacterium Combined With Mesalazine In The Treatment Of Mild And Moderate Ulcerative Colitis

Objective:Ulcerative colitis(UC)is an abnormal immune-mediated chronic non-specific colorectal inflammatory disease.Anti-inflammation and modulating immune response are the main treatment methods at present.In recent years,more attention has been paid to the treatment of UC with Microecologics.The purpose of this study was to observe the clinical efficacy of Bifidobacterium tetravaccine tablets(Live)combined with mesalazine in the treatment of patients with mild and moderate ulcerative colitis,evaluate its short-term prognosis,and explore relevant immunological mechanisms,so as to provide data support and theoretical basis for the development of a more scientific and reasonable clinical path for ulcerative colitis.Methods:A total of 72 cases of mild and moderate active ulcerative colitis were diagnosed in the second department of gastroenterology in the first central hospital of baoding according to the symptoms and endoscopic examination.The patients were divided into the combined medication group and the control group by random number table method,with 36 cases in each.The two groups of patients were given nutritional support,enema and other basic treatments,among which the control group was added with methalazine alone,while the combined medication group was treated with methalazine and bifidobacterium tetravaccine tablets(Live)for 8 weeks.The changes of c-reactive protein and Mayo scores before and after treatment in the two groups were observed and compared,and the remission rate,effective rate,the number of days of initial remission and complete remission were compared between these two groups.Patients in both groups who had complete remission were reduced to half dose at methalazine and maintained the original dose at bifidobacterium tetravaccine tablets(Live),continued maintenance treatment and were followed up for 6 months to compare the rate and the number of days of recurrence.Result:1.There was no significant difference in the c-reactive protein and Mayo scores before treatment between the combined medication group and the control group,but the c-reactive protein and Mayo scores of the combined medication group were significantly lower than those of the control group after treatment(P < 0.05),with statistically significant differences;2.After 8 weeks of treatment,the complete remission rate and effective rate of the combined medication group were higher than those of the control group(P < 0.05),with statistically significant differences;3.The number of days for patients in the combined medication group to begin and complete relief was smaller than that in the control group,and the difference was statistically significant(P < 0.05);4.Patients with complete remission in the two groups were followed up for 6 months,and there was no significant difference in the recurrence rate and recurrence days between the two groups(P > 0.05).Conclusion:1.In the treatment of mild and moderate active ulcerative colitis,the combination of Bifidobacterium and Mesalazine has better clinical effect than that of Mesalazine alone.2.In the maintenance treatment of inactive ulcerative colitis,the combination of Bifidobacterium and mesalazine showed no significant clinical benefit compared with the single application of mesalazine.